{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000006","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.982424+00:00","generated_at":"2026-06-20T17:54:26.606684+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure reports preliminary FY2022 net revenue $537.8M (+1% YoY); LUNAR study meets primary endpoint","bullets":["FY2022 net revenue $537.8M, +1% YoY; Q4 net revenue $128.4M, with US $98.6M, EMEA $17.0M, Japan $7.9M, Greater China $4.9M.","Cash, equivalents and short-term investments $969.4M as of Dec 31, 2022.","3,430 active patients; 1,373 prescriptions received in Q4 (North America 956, EMEA 312, Japan 105).","LUNAR study met primary endpoint: significant overall survival benefit with TTFields + immune checkpoint inhibitors in NSCLC.","New thinner/lighter arrays launched in Europe under limited market release; Health Canada approved Optune for GBM."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000006","json":"https://secwatch.observer/filing/0001645113-23-000006.json","markdown":"https://secwatch.observer/filing/0001645113-23-000006.md","text":"https://secwatch.observer/filing/0001645113-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/0001645113-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/nvcr-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:54:26.606684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27e5debb218ad2c444907a875963057c4cbb5444","claim":"NovoCure Ltd reported for the quarter and year ended December 31, 2022 results: revenue $537.8 million.","evidence_excerpt":"--- EX-99.1 (EX-99.1) --- Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/0001645113-23-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$537.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}